Corautus Genetics Inc. to Present at BIO 2006 Business Forum
04 4월 2006 - 11:00PM
PR Newswire (US)
ATLANTA, April 4 /PRNewswire-FirstCall/ -- Corautus Genetics Inc.
(NASDAQ:VEGF) today announced that the company will be presenting
at BIO 2006 Business Forum which is being held as part of BIO 2006,
the Biotechnology Industry Organization's Annual International
Convention being held at McCormick Place Convention Center in
Chicago, Illinois from April 9-12, 2006. Michael K. Steele, Vice
President-Business Development for Corautus Genetics, will be
giving the company's corporate presentation on Tuesday, April 11th,
at 11:45 a.m. in Room B, McCormick Place South, Level 3 Exhibit
Hall A. The Bio Business Forum is the largest partnering and
networking program in the industry. It is a program that offers
pharmaceutical companies, biotechnology companies, academic
research institutions and investors from around the world the
unique opportunity to gather in one place at one time to learn
about each other and to meet one-on-one to discuss business
opportunities of mutual interest. About Corautus Genetics Corautus
Genetics Inc. is a biopharmaceutical company dedicated to the
development and commercialization of innovative gene therapy
products for the treatment of cardiovascular (severe angina) and
peripheral vascular disease. Corautus is focusing its efforts and
resources on the development of gene therapy products using a
growth factor known as Vascular Endothelial Growth Factor-2, or
VEGF-2, gene to promote therapeutic angiogenesis in ischemic
muscle. Corautus has a strategic alliance with Boston Scientific
Corporation (NYSE:BSX) to develop, commercialize and distribute the
VEGF-2 gene therapy products. For more information, please visit
http://www.corautus.com/. Forward-Looking Statements This press
release may contain forward-looking statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Such statements are subject to certain factors, risks
and uncertainties that may cause actual results, events and
performances to differ materially from those referred to in such
statements. These risks include statements which address operating
performance, events or developments that we expect or anticipate
will occur in the future, such as projections about our ongoing
clinical trial, including its costs, potential benefits from
manufacturing agreements, the potential benefits from previous
clinical trials, sufficient and timely enrollment of suitable
patients in our clinical trial, future results of operations or our
financial condition, recommencement of our GENASIS trial, adequacy
of funding, benefits from the alliance with Boston Scientific,
research, development and commercialization of our product
candidates, anticipated trends in our business, manufacture of
sufficient and acceptable quantities of our proposed products,
approval of our product candidates, meeting additional capital
requirements, and other risks that could cause actual results to
differ materially. These risks are discussed in Corautus Genetics
Inc.'s Securities and Exchange Commission filings, including, but
not limited to, the risk factors in Corautus' 2005 Annual Report on
Form 10-K which was filed on March 20, 2006, which are incorporated
by reference into this press release. For more information, please
visit http://www.corautus.com/ . Company Contact: Michael K. Steele
Vice President - Business Development (404) 526-6212 Investor
Relations Contacts: Lippert/Heilshorn & Assoc Kim Sutton
Golodetz Anne Marie Fields 212-838-3777 DATASOURCE: Corautus
Genetics Inc. CONTACT: Michael K. Steele, Vice President-Business
Development of Corautus Genetics Inc., +1-404-526-6212, or ; or
Investor Relations, Kim Sutton Golodetz, , or Anne Marie Fields, ,
or +1-212-838-3777, of Lippert-Heilshorn & Assoc. Web site:
http://www.corautus.com/
Copyright
Corautus Genetics (NASDAQ:VEGF)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Corautus Genetics (NASDAQ:VEGF)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024